Albert David Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1296.00 +0.40 (0.03%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1236.4
Today’s High
1314.9
52 Week Low
912.1
52 Week High
1752.95
1271.05 -14.15 (-1.10%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1254.45
Today’s High
1309
52 Week Low
911.05
52 Week High
1753.95
Key Metrics
- Market Cap (In Cr) 733.41
- Beta 0.88
- Div. Yield (%) 0.89
- P/B 1.92
- TTM P/E 12.12
- Peg Ratio 0.21
- Sector P/E 31.15
- D/E 0.01
- Open Price 1278
- Prev Close 1295.6
Albert David Analysis
Price Analysis
-
1 Week-8.58%
-
3 Months3.63%
-
6 Month10.52%
-
YTD31.77%
-
1 Year38.08%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Albert David News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 26 Aug 2024The friendship with Warren Buffett that led to her $1 billion donation
9 min read . 02 Mar 2024Albert David Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 362.46
- Selling/ General/ Admin Expenses Total
- 88.43
- Depreciation/ Amortization
- 6.83
- Other Operating Expenses Total
- 100.75
- Total Operating Expense
- 322.41
- Operating Income
- 40.05
- Net Income Before Taxes
- 97.29
- Net Income
- 75.42
- Diluted Normalized EPS
- 132.15
- Period
- 2024
- Total Assets
- 497.99
- Total Liabilities
- 115.01
- Total Equity
- 382.98
- Tangible Book Valueper Share Common Eq
- 667.81
- Period
- 2024
- Cashfrom Operating Activities
- 45.5
- Cashfrom Investing Activities
- -33.25
- Cashfrom Financing Activities
- -8.27
- Net Changein Cash
- 3.99
- Period
- 2023
- Total Revenue
- 341.56
- Selling/ General/ Admin Expenses Total
- 94.79
- Depreciation/ Amortization
- 8.55
- Other Operating Expenses Total
- 56.48
- Total Operating Expense
- 305.32
- Operating Income
- 36.24
- Net Income Before Taxes
- 50.74
- Net Income
- 36.17
- Diluted Normalized EPS
- 63.36
- Period
- 2023
- Total Assets
- 423.39
- Total Liabilities
- 111.82
- Total Equity
- 311.57
- Tangible Book Valueper Share Common Eq
- 541.62
- Period
- 2023
- Cashfrom Operating Activities
- 10.52
- Cashfrom Investing Activities
- -5
- Cashfrom Financing Activities
- -6.36
- Net Changein Cash
- -0.83
- Period
- 2022
- Total Revenue
- 313.51
- Selling/ General/ Admin Expenses Total
- 97.76
- Depreciation/ Amortization
- 8.81
- Other Operating Expenses Total
- 43.22
- Total Operating Expense
- 281.52
- Operating Income
- 31.99
- Net Income Before Taxes
- 47.3
- Net Income
- 35.26
- Diluted Normalized EPS
- 58.71
- Period
- 2022
- Total Assets
- 401.23
- Total Liabilities
- 121.76
- Total Equity
- 279.47
- Tangible Book Valueper Share Common Eq
- 482.91
- Period
- 2022
- Cashfrom Operating Activities
- 40.41
- Cashfrom Investing Activities
- -39.7
- Cashfrom Financing Activities
- -1.59
- Net Changein Cash
- -0.8
- Period
- 2021
- Total Revenue
- 247.45
- Selling/ General/ Admin Expenses Total
- 93.36
- Depreciation/ Amortization
- 8.23
- Other Operating Expenses Total
- 36.71
- Total Operating Expense
- 236.5
- Operating Income
- 10.95
- Net Income Before Taxes
- 27.44
- Net Income
- 22.14
- Diluted Normalized EPS
- 38.69
- Period
- 2021
- Total Assets
- 341.4
- Total Liabilities
- 97.02
- Total Equity
- 244.38
- Tangible Book Valueper Share Common Eq
- 425.63
- Period
- 2021
- Cashfrom Operating Activities
- 36.61
- Cashfrom Investing Activities
- -38.68
- Cashfrom Financing Activities
- -1.7
- Net Changein Cash
- -3.77
- Period
- 2020
- Total Revenue
- 320.79
- Selling/ General/ Admin Expenses Total
- 104.07
- Depreciation/ Amortization
- 7.67
- Other Operating Expenses Total
- 60.01
- Total Operating Expense
- 294.6
- Operating Income
- 26.2
- Net Income Before Taxes
- 28.95
- Net Income
- 19.17
- Diluted Normalized EPS
- 33.43
- Period
- 2020
- Total Assets
- 320.22
- Total Liabilities
- 97.42
- Total Equity
- 222.8
- Tangible Book Valueper Share Common Eq
- 386.48
- Period
- 2020
- Cashfrom Operating Activities
- 30.25
- Cashfrom Investing Activities
- -20
- Cashfrom Financing Activities
- -10.33
- Net Changein Cash
- 0
- Period
- 2019
- Total Revenue
- 316.89
- Selling/ General/ Admin Expenses Total
- 162.19
- Depreciation/ Amortization
- 6.98
- Other Operating Expenses Total
- 0.7
- Total Operating Expense
- 293.71
- Operating Income
- 23.18
- Net Income Before Taxes
- 28.85
- Net Income
- 26.64
- Diluted Normalized EPS
- 31.14
- Period
- 2019
- Total Assets
- 294.61
- Total Liabilities
- 84.17
- Total Equity
- 210.45
- Tangible Book Valueper Share Common Eq
- 364.4
- Period
- 2019
- Cashfrom Operating Activities
- 31.96
- Cashfrom Investing Activities
- -19.16
- Cashfrom Financing Activities
- -17.09
- Net Changein Cash
- -4.3
- Period
- 2018
- Total Revenue
- 288.99
- Selling/ General/ Admin Expenses Total
- 84.54
- Depreciation/ Amortization
- 8.23
- Other Operating Expenses Total
- 90.26
- Total Operating Expense
- 275.5
- Operating Income
- 13.49
- Net Income Before Taxes
- 21.54
- Net Income
- 9.84
- Diluted Normalized EPS
- 20.52
- Period
- 2018
- Total Assets
- 289.74
- Total Liabilities
- 103.8
- Total Equity
- 185.95
- Tangible Book Valueper Share Common Eq
- 321.51
- Period
- 2018
- Cashfrom Operating Activities
- 30.01
- Cashfrom Investing Activities
- -11.03
- Cashfrom Financing Activities
- -4.56
- Net Changein Cash
- 14.62
- Period
- 2024-06-30
- Total Revenue
- 89.36
- Selling/ General/ Admin Expenses Total
- 28.37
- Depreciation/ Amortization
- 1.79
- Other Operating Expenses Total
- 29.81
- Total Operating Expense
- 90.26
- Operating Income
- -0.91
- Net Income Before Taxes
- 22.06
- Net Income
- 18.84
- Diluted Normalized EPS
- 33.02
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 89.06
- Selling/ General/ Admin Expenses Total
- 22.72
- Depreciation/ Amortization
- 1.83
- Other Operating Expenses Total
- 27.12
- Total Operating Expense
- 81.32
- Operating Income
- 7.74
- Net Income Before Taxes
- 18.11
- Net Income
- 12.91
- Diluted Normalized EPS
- 22.63
- Period
- 2024-03-31
- Total Assets
- 497.99
- Total Liabilities
- 115.01
- Total Equity
- 382.98
- Tangible Book Valueper Share Common Eq
- 667.81
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 45.5
- Cashfrom Investing Activities
- -33.25
- Cashfrom Financing Activities
- -8.27
- Net Changein Cash
- 3.99
- Period
- 2023-12-31
- Total Revenue
- 88.28
- Selling/ General/ Admin Expenses Total
- 23.09
- Depreciation/ Amortization
- 1.68
- Other Operating Expenses Total
- 24.04
- Total Operating Expense
- 81.61
- Operating Income
- 6.67
- Net Income Before Taxes
- 23.44
- Net Income
- 18.72
- Diluted Normalized EPS
- 32.8
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 93.18
- Selling/ General/ Admin Expenses Total
- 20.43
- Depreciation/ Amortization
- 1.46
- Other Operating Expenses Total
- 25.14
- Total Operating Expense
- 78.67
- Operating Income
- 14.51
- Net Income Before Taxes
- 26.55
- Net Income
- 20.3
- Diluted Normalized EPS
- 35.57
- Period
- 2023-09-30
- Total Assets
- 454.55
- Total Liabilities
- 104.26
- Total Equity
- 350.29
- Tangible Book Valueper Share Common Eq
- 610.06
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 31.05
- Cashfrom Investing Activities
- -17.96
- Cashfrom Financing Activities
- -9.75
- Net Changein Cash
- 3.38
- Period
- 2023-06-30
- Total Revenue
- 91.95
- Selling/ General/ Admin Expenses Total
- 22.2
- Depreciation/ Amortization
- 1.85
- Other Operating Expenses Total
- 25.07
- Total Operating Expense
- 80.81
- Operating Income
- 11.14
- Net Income Before Taxes
- 29.19
- Net Income
- 23.49
- Diluted Normalized EPS
- 41.16
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 81.42
- Selling/ General/ Admin Expenses Total
- 17.23
- Depreciation/ Amortization
- 2.3
- Other Operating Expenses Total
- 24.17
- Total Operating Expense
- 74.13
- Operating Income
- 7.29
- Net Income Before Taxes
- 7.19
- Net Income
- 3.73
- Diluted Normalized EPS
- 6.54
- Period
- 2023-03-31
- Total Assets
- 423.39
- Total Liabilities
- 111.82
- Total Equity
- 311.57
- Tangible Book Valueper Share Common Eq
- 541.62
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 10.52
- Cashfrom Investing Activities
- -5
- Cashfrom Financing Activities
- -6.36
- Net Changein Cash
- -0.83
- Period
- 2022-12-31
- Total Revenue
- 74.57
- Selling/ General/ Admin Expenses Total
- 20.3
- Depreciation/ Amortization
- 2.06
- Other Operating Expenses Total
- 21.63
- Total Operating Expense
- 68.34
- Operating Income
- 6.23
- Net Income Before Taxes
- 13.58
- Net Income
- 10.55
- Diluted Normalized EPS
- 18.48
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Albert David Technical
Moving Average
SMA
- 5 Day1340.38
- 10 Day1356.7
- 20 Day1364.92
- 50 Day1426.16
- 100 Day1373.77
- 300 Day1295.89
Albert David Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Nectar Lifesciences
- 34.2
- -0.69
- -1.98
- 56.39
- 25.02
- 766.97
- Wanbury
- 211
- -11
- -4.95
- 291
- 91
- 690.93
- Albert David
- 1296
- 0.4
- 0.03
- 1752.95
- 912.1
- 739.65
- Titan Biotech
- 757
- -11.7
- -1.52
- 1017.85
- 375
- 625.56
- Medicamen Biotech
- 434.05
- -15.05
- -3.35
- 661.85
- 356.75
- 551.88
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Nectar Lifesciences
- 157.05
- 0.73
- -0.65
- -0.41
- Wanbury
- 24.51
- 26.31
- -
- 7.62
- Albert David
- 9.67
- 1.92
- 13.89
- 11.87
- Titan Biotech
- 25.56
- 4.76
- 28.11
- 16.21
- Medicamen Biotech
- 51.91
- 2.75
- 8.92
- 9.58
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 13-May-24
- Audited Results & Final Dividend
- 05-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Dividend
- 13-Feb-23
- Quarterly Results
- 12-Nov-22
- Quarterly Results
- 09-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 09-Aug-24
- 13-May-24
- AGM
- 18-Dec-23
- 15-Nov-23
- POM
- 10-Aug-23
- 18-Jul-23
- AGM
- 09-Aug-22
- 05-Jul-22
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 13-May-24
- 02-Aug-24
- 02-Aug-24
- 11.5
- 19-May-23
- 03-Aug-23
- 03-Aug-23
- 9
- 11-May-22
- 02-Aug-22
- 01-Aug-22
- 9
- 17-Jun-21
- 07-Sept-21
- 06-Sept-21
- 6